Synthesis and evaluation of small libraries of triazolylmethoxy chalcones, flavanones and 2-aminopyrimidines as inhibitors of mycobacterial FAS-II and PknG.

A synthetic strategy to access small libraries of triazolylmethoxy chalcones 4{1-20}, triazolylmethoxy flavanones 5{1-10} and triazolylmethoxy aminopyrimidines 6{1-17} from a common substrate 4-propargyloxy-2-hydroxy acetophenone using a set of different reactions has been developed. The chalcones and flavanones were screened against mycobacterial FAS-II pathway using a recombinant mycobacterial strain, against which the most potent compound showed ∼88% inhibition in bacterial growth and substantially induction of reporter gene activity at 100 μM concentration. The triazolylmethoxy aminopyrimdines were screened against PknG of Mycobaceterium tuberculosis displaying moderate to good activity (23-53% inhibition at 100 μM), comparable to the action of a standard inhibitor.

[1]  J. Heilmann,et al.  Natural and non-natural prenylated chalcones: synthesis, cytotoxicity and anti-oxidative activity. , 2008, Bioorganic & medicinal chemistry.

[2]  Kelly E Heim,et al.  Flavonoid antioxidants: chemistry, metabolism and structure-activity relationships. , 2002, The Journal of nutritional biochemistry.

[3]  B. Kumar,et al.  Preparation and reactions of sugar azides with alkynes: synthesis of sugar triazoles as antitubercular agents. , 2008, Carbohydrate research.

[4]  M. Iinuma,et al.  Anti-Candida activity of synthetic hydroxychalcones. , 1994, Die Pharmazie.

[5]  C. A. Fraga.  Drug hybridization strategies: before or after lead identification? , 2009, Expert opinion on drug discovery.

[6]  Li-Ming Zhou,et al.  Chalcones and flavonoids as anti-tuberculosis agents. , 2002, Bioorganic & medicinal chemistry.

[7]  M. Steinmetz,et al.  Structural basis for the specific inhibition of protein kinase G, a virulence factor of Mycobacterium tuberculosis , 2007, Proceedings of the National Academy of Sciences.

[8]  H. Harada,et al.  Synthesis and biological evaluation of indolyl chalcones as antitumor agents. , 2010, Bioorganic & medicinal chemistry letters.

[9]  A. Mascarello,et al.  Synthetic chalcones as efficient inhibitors of Mycobacterium tuberculosis protein tyrosine phosphatase PtpA. , 2008, Bioorganic & medicinal chemistry letters.

[10]  Y. Tzeng,et al.  Synthesis and biological evaluation of 3',4',5'-trimethoxychalcone analogues as inhibitors of nitric oxide production and tumor cell proliferation. , 2009, Bioorganic & medicinal chemistry.

[11]  A. Srivastava,et al.  Application of click chemistry towards an efficient synthesis of 1,2,3-1H-triazolyl glycohybrids as enzyme inhibitors. , 2011, Carbohydrate research.

[12]  G. Besra,et al.  Flavonoid inhibitors as novel antimycobacterial agents targeting Rv0636, a putative dehydratase enzyme involved in Mycobacterium tuberculosis fatty acid synthase II. , 2007, Microbiology.

[13]  J. Naismith,et al.  Novel inhibitors of an emerging target in Mycobacterium tuberculosis; substituted thiazolidinones as inhibitors of dTDP-rhamnose synthesis. , 2003, Bioorganic & medicinal chemistry letters.

[14]  J. Gut,et al.  Design, synthesis and in vitro antimalarial evaluation of triazole-linked chalcone and dienone hybrid compounds. , 2010, Bioorganic & medicinal chemistry.

[15]  Abhishek Sharma,et al.  Reinvestigation of structure-activity relationship of methoxylated chalcones as antimalarials: synthesis and evaluation of 2,4,5-trimethoxy substituted patterns as lead candidates derived from abundantly available natural β-asarone. , 2010, European journal of medicinal chemistry.

[16]  A. Bell,et al.  Hybrid drugs for malaria. , 2009, Current pharmaceutical design.

[17]  J. Heilmann,et al.  Synthesis, cytotoxicity, anti-oxidative and anti-inflammatory activity of chalcones and influence of A-ring modifications on the pharmacological effect. , 2010, European journal of medicinal chemistry.

[18]  H. Wilkinson,et al.  Estrogen receptor ligands. Part 10: Chromanes: old scaffolds for new SERAMs. , 2005, Bioorganic & medicinal chemistry letters.

[19]  I. Wilson,et al.  Investigation of the Alamar Blue (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity. , 2000, European journal of biochemistry.

[20]  H. Rajak,et al.  Synthesis and biological evaluation of novel benzothiazole clubbed fluoroquinolone derivatives , 2013, Journal of enzyme inhibition and medicinal chemistry.

[21]  V. Chaturvedi,et al.  Synthesis, molecular modeling and bio-evaluation of cycloalkyl fused 2-aminopyrimidines as antitubercular and antidiabetic agents. , 2011, Bioorganic & medicinal chemistry letters.

[22]  Liem Nguyen,et al.  Protein Kinase G from Pathogenic Mycobacteria Promotes Survival Within Macrophages , 2004, Science.

[23]  Nitin Gupta,et al.  Deciphering kas operon locus in Mycobacterium aurum and genesis of a recombinant strain for rational‐based drug screening , 2008, Journal of applied microbiology.

[24]  M. Doble,et al.  Synthesis, Biological Evaluation, Mechanism of Action and Quantitative Structure–Activity Relationship Studies of Chalcones as Antibacterial Agents , 2009, Chemical biology & drug design.

[25]  J. Schaeffer,et al.  Estrogen receptor ligands. Part 1: The discovery of flavanoids with subtype selectivity. , 2004, Bioorganic & medicinal chemistry letters.

[26]  E. Barreiro,et al.  Molecular hybridization: a useful tool in the design of new drug prototypes. , 2007, Current medicinal chemistry.

[27]  S. Lociuro,et al.  Dihydrofolate reductase inhibitors as antibacterial agents. , 2006, Biochemical pharmacology.

[28]  Ashutosh Kumar,et al.  Virtual screening against Mycobacterium tuberculosis dihydrofolate reductase: suggested workflow for compound prioritization using structure interaction fingerprints. , 2008, Journal of molecular graphics & modelling.

[29]  J. Gut,et al.  Synthesis and antimalarial activity of sulfonamide chalcone derivatives. , 2005, Farmaco.

[30]  A. Ajay,et al.  Synthesis and bio-evaluation of alkylaminoaryl phenyl cyclopropyl methanones as antitubercular and antimalarial agents. , 2010, Bioorganic & medicinal chemistry.

[31]  Alex Matter,et al.  Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug , 2002, Nature Reviews Drug Discovery.

[32]  Yasuo Konishi,et al.  Drug evolution concept in drug design: 1. Hybridization method. , 2004 .

[33]  E. Koroleva,et al.  Synthesis and applications of 2-aminopyrimidine derivatives as key intermediates in chemical synthesis of biomolecules , 2010 .